Corrigendum to “APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome” [Neurobiology of Disease 67 (2014) 24–36] (Neurobiology of Disease (2014) 67 (24–36), (S0969996114000576), (10.1016/j.nbd.2014.03.003));APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome

Neurobiology of Disease

Volumn 67, Issue , 2014, Pages 24-36

  Trazzi, Stefania ^a   Fuchs, Claudia ^a   De Franceschi, Marianna ^a   Mitrugno, Valentina Maria ^a   Bartesaghi, Renata ^a   Ciani, Elisabetta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 HT1A receptor; AICD; APP; Down syndrome; Fluoxetine; GSK3 ; Lithium; Neurogenesis impairment

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADULT STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FETUS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR DYNAMICS; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRISOMY; ANIMAL; BRAIN; DISEASE MODEL; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FETUS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, TRANSGENIC; NEURAL STEM CELLS; NEUROGENESIS; PHOSPHORYLATION;

EID: 84897568647     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2020.104769     Document Type: Erratum

References (68)

1. Baek S.H., Ohgi K.A., Rose D.W., Koo E.H., Glass C.K., Rosenfeld M.G. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 2002, 110:55-67.
2. Beaulieu J.M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int. J. Neuropsychopharmacol. 2007, 10:3-6.
3. Becker L.E. Synaptic dysgenesis. Can. J. Neurol. Sci. 1991, 18:170-180.
4. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010, 20:106-118.
5. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
6. Cao X., Sudhof T.C. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
7. Chakrabarti L., Galdzicki Z., Haydar T.F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 2007, 27:11483-11495.
8. Chang K.A., Kim H.S., Ha T.Y., Ha J.W., Shin K.Y., Jeong Y.H., Lee J.P., Park C.H., Kim S., Baik T.K., Suh Y.H. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol. Cell. Biol. 2006, 26:4327-4338.
9. Chenn A., Walsh C.A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 2002, 297:365-369.
10. Chenn A., Walsh C.A. Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb. Cortex 2003, 13:599-606.
11. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
12. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2013, 123:348-361.
13. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995, 378:785-789.
14. Eldar-Finkelman H., Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front. Mol. Neurosci. 2011, 4:32.
15. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 2002, 22:2099-2110.
16. Fukata Y., Itoh T.J., Kimura T., Menager C., Nishimura T., Shiromizu T., Watanabe H., Inagaki N., Iwamatsu A., Hotani H., Kaibuchi K. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat. Cell Biol. 2002, 4:583-591.
17. Gao Y., Pimplikar S.W. The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14979-14984.
18. Ghosal K., Stathopoulos A., Pimplikar S.W. APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 2010, 5:e11866.
19. Gomez de Barreda E., Perez M., Gomez Ramos P., de Cristobal J., Martin-Maestro P., Moran A., Dawson H.N., Vitek M.P., Lucas J.J., Hernandez F., Avila J. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol. Dis. 2010, 37:622-629.
20. Guidi S., Bonasoni P., Ceccarelli C., Santini D., Gualtieri F., Ciani E., Bartesaghi R. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 2008, 18:180-197.
21. Guidi S., Ciani E., Bonasoni P., Santini D., Bartesaghi R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol. 2011, 21:361-373.
22. Guidi S., Stagni F., Bianchi P., Ciani E., Ragazzi E., Trazzi S., Grossi G., Mangano C., Calza L., Bartesaghi R. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol. 2013, 23:129-143.
23. Haydar T.F., Nowakowski R.S., Yarowsky P.J., Krueger B.K. Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J. Neurosci. 2000, 20:4156-4164.
24. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 11:539-551.
25. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998, 17:1371-1384.
26. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 2003, 24:441-443.
27. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
28. Kang H.J., Noh J.S., Bae Y.S., Gwag B.J. Calcium-dependent prevention of neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase and phospholipase Cgamma. Mol. Pharmacol. 2003, 64:228-234.
29. Kim Y.T., Hur E.M., Snider W.D., Zhou F.Q. Role of GSK3 signaling in neuronal morphogenesis. Front. Mol. Neurosci. 2011, 4:48.
30. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8455-8459.
31. Konietzko U. AICD nuclear signaling and its possible contribution to Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:200-216.
32. Lei P., Ayton S., Bush A.I., Adlard P.A. GSK-3 in neurodegenerative diseases. Int. J. Alzheimers Dis. 2011, 2011:189246.
33. Leissring M.A., Murphy M.P., Mead T.R., Akbari Y., Sugarman M.C., Jannatipour M., Anliker B., Muller U., Saftig P., De Strooper B., Wolfe M.S., Golde T.E., LaFerla F.M. A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4697-4702.
34. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
35. Lim C.S., Walikonis R.S. Hepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathway. Cell. Signal. 2008, 20:825-835.
36. Lin C.H., Tsai P.I., Wu R.M., Chien C.T. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J. Neurosci. 2010, 30:13138-13149.
37. Liu D.P., Schmidt C., Billings T., Davisson M.T. Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques 2003, 35:1170-1174. (1176, 1178 passim).
38. Lorenzi H.A., Reeves R.H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res. 2006, 1104:153-159.
39. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
40. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev. 2008, 28:773-796.
41. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 2004, 5:691-701.
42. Muller T., Meyer H.E., Egensperger R., Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 2008, 85:393-406.
43. Nalivaeva N.N., Turner A.J. The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett. 2013, 587:2046-2054.
44. Naska S., Park K.J., Hannigan G.E., Dedhar S., Miller F.D., Kaplan D.R. An essential role for the integrin-linked kinase-glycogen synthase kinase-3 beta pathway during dendrite initiation and growth. J. Neurosci. 2006, 26:13344-13356.
45. Nemoto T., Yanagita T., Kanai T., Wada A. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: the role of GSK-3beta in the maintenance of steady-state levels of insulin receptor signaling molecules and Na(v)1.7 sodium channel in adrenal chromaffin cells. J. Pharmacol. Sci. 2009, 109:157-161.
46. Pardo R., Andreolotti A.G., Ramos B., Picatoste F., Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J. Neurochem. 2003, 87:417-426.
47. Polter A.M., Yang S., Jope R.S., Li X. Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell. Signal. 2012, 24:265-271.
48. Prinz M., Prinz B., Schulz E. The growth of non-pyramidal neurons in the primary motor cortex of man: a Golgi study. Histol. Histopathol. 1997, 12:895-900.
49. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
50. Reinholdt L.G., Ding Y., Gilbert G.J., Czechanski A., Solzak J.P., Roper R.J., Johnson M.T., Donahue L.R., Lutz C., Davisson M.T. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm. Genome 2011, 22:685-691.
51. Roper R.J., Baxter L.L., Saran N.G., Klinedinst D.K., Beachy P.A., Reeves R.H. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1452-1456.
52. Ryan K.A., Pimplikar S.W. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell Biol. 2005, 171:327-335.
53. Salcedo-Tello P., Ortiz-Matamoros A., Arias C. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int. J. Alzheimers Dis. 2011, 2011:189728.
54. Sasaki T., Han F., Shioda N., Moriguchi S., Kasahara J., Ishiguro K., Fukunaga K. Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 2006, 1108:98-106.
55. Schulz E., Scholz B. Neurohistological findings in the parietal cortex of children with chromosome aberrations. J. Hirnforsch. 1992, 33:37-62.
56. Sturgeon X., Gardiner K.J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 2011, 22:261-271.
57. Takashima S., Becker L.E., Armstrong D.L., Chan F. Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative Golgi study. Brain Res. 1981, 225:1-21.
58. Takashima S., Ieshima A., Nakamura H., Becker L.E. Dendrites, dementia and the Down syndrome. Brain Dev. 1989, 11:131-133.
59. Tan M., Ma S., Huang Q., Hu K., Song B., Li M. GSK-3alpha/beta-mediated phosphorylation of CRMP-2 regulates activity-dependent dendritic growth. J. Neurochem. 2013, 125:685-697.
60. Tilleman K., Stevens I., Spittaels K., Haute C.V., Clerens S., Van Den Bergh G., Geerts H., Van Leuven F., Vandesande F., Moens L. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics 2002, 2:94-104.
61. Toledo E.M., Colombres M., Inestrosa N.C. Wnt signaling in neuroprotection and stem cell differentiation. Prog. Neurobiol. 2008, 86:281-296.
62. Trazzi S., Mitrugno V.M., Valli E., Fuchs C., Rizzi S., Guidi S., Perini G., Bartesaghi R., Ciani E. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum. Mol. Genet. 2011, 20:1560-1573.
63. Trazzi S., Fuchs C., Valli E., Perini G., Bartesaghi R., Ciani E. The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. J. Biol. Chem. 2013, 288:20817-20829.
64. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front. Biosci. 2009, 14:1558-1570.
65. Yao H.B., Shaw P.C., Wong C.C., Wan D.C. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J. Chem. Neuroanat. 2002, 23:291-297.
66. Yoshimura T., Kawano Y., Arimura N., Kawabata S., Kikuchi A., Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005, 120:137-149.
67. Zhou F., Gong K., van Laar T., Gong Y., Zhang L. Wnt/beta-catenin signal pathway stabilizes APP intracellular domain (AICD) and promotes its transcriptional activity. Biochem. Biophys. Res. Commun. 2011, 412:68-73.
68. Zhou F., Gong K., Song B., Ma T., van Laar T., Gong Y., Zhang L. The APP intracellular domain (AICD) inhibits Wnt signalling and promotes neurite outgrowth. Biochim. Biophys. Acta 2012, 1823:1233-1241.